{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-003572","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.226208+00:00","generated_at":"2026-06-18T04:16:09.495127+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Omeros Q4 net income $128.7M on $200M milestone; OMIDRIA royalties record $35.8M sales","bullets":["Q4 net loss from continuing ops $46.0M ($0.73/share) vs $54.8M loss in Q3; cash burn $26M.","Received $200M milestone from Rayner in Feb 2023; OMIDRIA Q4 royalties $17.9M on record $35.8M sales.","Cash and short-term investments $194.9M; accounts receivable $213M now collected; no SVB exposure.","Preparing narsoplimab BLA resubmission for TA-TMA; FDA meeting expected Q2 2023; ARTEMIS-IGAN data Q3 2023.","Initiated OMS906 trials in PNH (treatment-naïve and ravulizumab inadequate response) and C3G; OMS1029 quarterly dosing possible."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-003572","json":"https://secwatch.observer/filing/0001558370-23-003572.json","markdown":"https://secwatch.observer/filing/0001558370-23-003572.md","text":"https://secwatch.observer/filing/0001558370-23-003572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023003572/0001558370-23-003572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023003572/omer-20230313x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:16:09.495127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e50343429a3709671ae456f08f17b1ea7513b01","claim":"OMEROS CORP reported the year ended December 31, 2022 results: net income $47.4 million, EPS $0.76 per share.","evidence_excerpt":"For the year ended December 31, 2022, net income was $47.4 million, or $0.76 per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023003572/0001558370-23-003572-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$47.4 million"},{"label":"EPS","value":"$0.76 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"baa4e4f966635382aa5a00d1481298350bee16a7","claim":"OMEROS CORP reported the fourth quarter ended December 31, 2022 results: net income $128.7 million, EPS $2.05 per share.","evidence_excerpt":"Net income in the fourth quarter of 2022 was $128.7 million, or $2.05 per share, compared to a net loss in the third quarter of 2022 of $17.5 million, or $0.28 per share;","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023003572/0001558370-23-003572-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"$128.7 million"},{"label":"EPS","value":"$2.05 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}